BioWorld

July 17, 2006

Patient Death In ConjuChem Phase II Trial Halts Dosing

ConjuChem Biotechnologies Inc. discontinued dosing in a Phase II trial of its growth hormone product, DAC:GRF in HIV lipodystrophy, pending an investigation into the death of a patient. (BioWorld Today) Read More

FDA Says Nastech's Calcitonin-Salmon Spray Not Approvable

Official 2006 List Of Buzzwords, Passé Terms, Fatigued Phrases

DeCode Stock Sale To Raise $30M For Multidrug Pipeline

Latest BioLineRx In-License: Oral Peptide Drug For Obesity

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Businesswoman pressing dollar sign on touchscreen

JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

BioWorld

It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...